Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10...

kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and...

Zonegran, before Élan transferred their interests in zonisamide to Eisai Co., Ltd. in 2004. Eisai also markets Zonegran in Asia (China, Taiwan, and fourteen others)...

2024. Retrieved 19 February 2024. "Eisai Announces Japan Launch Of Anticancer Agent Halaven" (Press release). Eisai Co., Ltd. 19 July 2011. Retrieved 15...

under the brand name Fycompa, is an anti-epileptic medication developed by Eisai Co. that is used in addition to other drugs to treat partial seizures and...

Akynzeo (netupitant/palonosetron), for nausea and vomiting, licensed by Eisai Co. and Helsinn Therapeutics. Alecensa (alectinib), for ALK-positive non-small...

"EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO® (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN | News Release：2020 | Eisai Co...

Chugai Pharmaceutical Co., Ltd. (TYO: 4519) Daiichi Sankyo Company, Limited (TYO: 4568) Eisai Co., Ltd. (TYO: 4523) Kyowa Hakko Kirin Co., Ltd. (TYO: 4151)...

2017, Arena announced that it is selling Belviq to its Japanese partner, Eisai Co. Ltd., which will manufacture and market the drug; Arena will draw a royalty...

(now called Donepezil), an acetylcholinesterase inhibitor, first began at Eisai's Tsukuba Research Laboratories in 1983, because his mother suffered from...